{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:42:19Z","timestamp":1761100939120},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2006,8,1]],"date-time":"2006-08-01T00:00:00Z","timestamp":1154390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2006,8,1]],"date-time":"2006-08-01T00:00:00Z","timestamp":1154390400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2006,8]]},"DOI":"10.1007\/s11864-006-0038-1","type":"journal-article","created":{"date-parts":[[2007,7,4]],"date-time":"2007-07-04T18:21:58Z","timestamp":1183573318000},"page":"285-294","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":68,"title":["Inhibition of the phosphatidylinositol 3-kinase\/mammalian target of rapamycin pathway in hematologic malignancies"],"prefix":"10.1007","volume":"7","author":[{"given":"Thomas E.","family":"Witzig","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott H.","family":"Kaufmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"38_CR1","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/nrc1362","volume":"4","author":"MA Bjornsti","year":"2004","unstructured":"Bjornsti MA, Houghton PJ: The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004, 4:335\u2013348.","journal-title":"Nat Rev Cancer"},{"key":"38_CR2","doi-asserted-by":"publisher","first-page":"2954","DOI":"10.1200\/JCO.2004.02.141","volume":"22","author":"I Sansal","year":"2004","unstructured":"Sansal I, Sellers WR: The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 2004, 22:2954\u20132963.","journal-title":"J Clin Oncol"},{"key":"38_CR3","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/nrc1819","volume":"6","author":"M Cully","year":"2006","unstructured":"Cully M, You H, Levine AJ, Mak TW: Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer 2006, 6:184\u2013192. This article provides an excellent overview of the PI3-K pathway, with special reference to oncology.","journal-title":"Nat Rev Cancer"},{"key":"38_CR4","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.semcdb.2004.01.002","volume":"15","author":"J Downward","year":"2004","unstructured":"Downward J: PI 3-kinase, Akt and cell survival. Semin Cell Dev Biol 2004, 15:177\u2013182.","journal-title":"Semin Cell Dev Biol"},{"key":"38_CR5","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.cell.2006.01.016","volume":"124","author":"S Wullschleger","year":"2006","unstructured":"Wullschleger S, Loewith R, Hall MN: TOR signaling in growth and metabolism. Cell 2006, 124:471\u2013484.","journal-title":"Cell"},{"key":"38_CR6","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1126\/science.296.5573.1655","volume":"296","author":"LC Cantley","year":"2002","unstructured":"Cantley LC: The phosphoinositide 3-kinase pathway. Science 2002, 296:1655\u20131657.","journal-title":"Science"},{"key":"38_CR7","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1038\/nrc1753","volume":"5","author":"AG Bader","year":"2005","unstructured":"Bader AG, Kang S, Zhao L, Vogt PK: Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer 2005, 5:921\u2013929.","journal-title":"Nat Rev Cancer"},{"key":"38_CR8","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1158\/1078-0432.CCR-05-1362","volume":"12","author":"E Conde","year":"2006","unstructured":"Conde E, Angulo B, Tang M, et al.: Molecular context of the EGFR mutations: evidence for the activation of mTOR\/S6K signaling. Clin Cancer Res 2006, 12:710\u2013717.","journal-title":"Clin Cancer Res"},{"key":"38_CR9","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1158\/0008-5472.CAN-05-2925","volume":"66","author":"KE O'Reilly","year":"2006","unstructured":"O'Reilly KE, Rojo F, She Q et al.: mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006, 66:1500\u20131508.","journal-title":"Cancer Res"},{"key":"38_CR10","doi-asserted-by":"crossref","first-page":"6541","DOI":"10.1002\/j.1460-2075.1996.tb01045.x","volume":"15","author":"DR Alessi","year":"1996","unstructured":"Alessi DR, Andjelkovic M, Caudwell B, et al.: Mechanism of activation of protein kinase B by insulin and IGF-1. Embo J 1996, 15:6541\u20136551.","journal-title":"Embo J"},{"key":"38_CR11","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1158\/0008-5472.CAN-04-3888","volume":"65","author":"MG Kharas","year":"2005","unstructured":"Kharas MG, Fruman DA: ABL oncogenes and phosphoinositide 3-kinase: mechanism of activation and downstream effectors. Cancer Res 2005, 65:2047\u20132053.","journal-title":"Cancer Res"},{"key":"38_CR12","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/370527a0","volume":"370","author":"P Rodriguez-Viciana","year":"1994","unstructured":"Rodriguez-Viciana P, Warne PH, Dhand R, et al.: Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 1994, 370:527\u2013532.","journal-title":"Nature"},{"key":"38_CR13","doi-asserted-by":"publisher","first-page":"4217","DOI":"10.1200\/JCO.2004.01.103","volume":"22","author":"JE Thompson","year":"2004","unstructured":"Thompson JE, Thompson CB: Putting the Rap on Akt. J Clin Oncol 2004, 22:4217\u20134226.","journal-title":"J Clin Oncol"},{"key":"38_CR14","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/S0898-6568(01)00271-6","volume":"14","author":"KM Nicholson","year":"2002","unstructured":"Nicholson KM, Anderson NG: The protein kinase B\/Akt signalling pathway in human malignancy. Cell Signal 2002, 14:381\u2013395.","journal-title":"Cell Signal"},{"key":"38_CR15","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/S0968-0004(01)01958-2","volume":"26","author":"DP Brazil","year":"2001","unstructured":"Brazil DP, Hemmings BA: Ten years of protein kinase B signalling: a hard Akt to follow. Trends Biochem Sci 2001, 26:657\u2013664.","journal-title":"Trends Biochem Sci"},{"key":"38_CR16","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1073\/pnas.0510857103","volume":"103","author":"AG Bader","year":"2006","unstructured":"Bader AG, Kang S, Vogt PK: Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc Natl Acad Sci U S A 2006, 103:1475\u20131479.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"38_CR17","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/ni0302-221","volume":"3","author":"M Karin","year":"2002","unstructured":"Karin M, Lin A: NF-kappaB at the crossroads of life and death. Nat Immunol 2002, 3:221\u2013227.","journal-title":"Nat Immunol"},{"key":"38_CR18","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.tips.2004.12.011","volume":"26","author":"Z Luo","year":"2005","unstructured":"Luo Z, Saha AK, Xiang X, Ruderman NB: AMPK, the metabolic syndrome and cancer. Trends Pharmacol Sci 2005, 26:69\u201376.","journal-title":"Trends Pharmacol Sci"},{"key":"38_CR19","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1126\/science.277.5322.99","volume":"277","author":"GJ Brunn","year":"1997","unstructured":"Brunn GJ, Hudson CC, Sekulic A, et al.: Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin. Science 1997, 277:99\u2013101.","journal-title":"Science"},{"key":"38_CR20","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1073\/pnas.95.4.1432","volume":"95","author":"PE Burnett","year":"1998","unstructured":"Burnett PE, Barrow RK, Cohen NA, et al.: RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1. Proc Natl Acad Sci U S A 1998, 95:1432\u20131437.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"38_CR21","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1101\/gad.887201","volume":"15","author":"AC Gingras","year":"2001","unstructured":"Gingras AC, Raught B, Sonenberg N: Regulation of translation initiation by FRAP\/mTOR. Genes Dev 2001, 15:807\u2013826.","journal-title":"Genes Dev"},{"key":"38_CR22","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1101\/gad.1212704","volume":"18","author":"N Hay","year":"2004","unstructured":"Hay N, Sonenberg N: Upstream and downstream of mTOR. Genes Dev 2004, 18:1926\u20131945.","journal-title":"Genes Dev"},{"key":"38_CR23","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1101\/gad.13.11.1422","volume":"13","author":"AC Gingras","year":"1999","unstructured":"Gingras AC, Gygi SP, Raught B, et al.: Regulation of 4EBP1 phosphorylation: a novel two-step mechanism. Genes Dev 1999, 13:1422\u20131437.","journal-title":"Genes Dev"},{"key":"38_CR24","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/S0092-8674(00)00117-3","volume":"103","author":"T Schmelzle","year":"2000","unstructured":"Schmelzle T, Hall MN: TOR, a central controller of cell growth. Cell 2000, 103:253\u2013262.","journal-title":"Cell"},{"key":"38_CR25","doi-asserted-by":"publisher","first-page":"22175","DOI":"10.1074\/jbc.M202014200","volume":"277","author":"A Grolleau","year":"2002","unstructured":"Grolleau A, Bowman J, Pradet-Balade B, et al.: Global and specific translational control by rapamycin in T cells uncovered by microarrays and proteomics. J Biol Chem 2002, 277:22175\u201322184.","journal-title":"J Biol Chem"},{"key":"38_CR26","doi-asserted-by":"publisher","first-page":"7004","DOI":"10.1128\/MCB.22.20.7004-7014.2002","volume":"22","author":"CC Hudson","year":"2002","unstructured":"Hudson CC, Liu M, Chiang GG, et al.: Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol 2002, 22:7004\u20137014.","journal-title":"Mol Cell Biol"},{"key":"38_CR27","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/nm1337","volume":"12","author":"GV Thomas","year":"2006","unstructured":"Thomas GV, Tran C, Mellinghoff IK, et al.: Hypoxiainducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 2006, 12:122\u2013127.","journal-title":"Nat Med"},{"key":"38_CR28","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S0092-8674(00)80674-1","volume":"100","author":"Cristofano A Di","year":"2000","unstructured":"Di Cristofano A, Pandolfi PP: The multiple roles of PTEN in tumor suppression. Cell 2000, 100:387\u2013390.","journal-title":"Cell"},{"key":"38_CR29","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1126\/science.1106148","volume":"307","author":"DD Sarbassov","year":"2005","unstructured":"Sarbassov DD, Guertin DA, Ali SM, Sabatini DM: Phosphorylation and regulation of Akt\/PKB by the rictormTOR complex. Science 2005, 307:1098\u20131101.","journal-title":"Science"},{"key":"38_CR30","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1038\/nrd1902","volume":"4","author":"BT Hennessy","year":"2005","unstructured":"Hennessy BT, Smith DL, Ram PT, et al.: Exploiting the PI3K\/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 2005, 4:988\u20131004.","journal-title":"Nat Rev Drug Discov"},{"key":"38_CR31","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1093\/jnci\/91.22.1922","volume":"91","author":"IU Ali","year":"1999","unstructured":"Ali IU, Schriml LM, Dean M: Mutational spectra of PTEN\/MMAC1 gene: a tumor suppressor with lipid phosphatase activity. J Natl Cancer Inst 1999, 91:1922\u20131932.","journal-title":"J Natl Cancer Inst"},{"key":"38_CR32","first-page":"3986","volume":"61","author":"J Brognard","year":"2001","unstructured":"Brognard J, Clark AS, Ni Y, Dennis PA: Akt\/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 2001, 61:3986\u20133997.","journal-title":"Cancer Res"},{"key":"38_CR33","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1158\/1078-0432.CCR-05-1654","volume":"12","author":"CA Granville","year":"2006","unstructured":"Granville CA, Memmott RM, Gills JJ, Dennis PA: Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase\/Akt\/mammalian target of rapamycin pathway. Clin Cancer Res 2006, 12:679\u2013689. A detailed discussion and review of the drugs in various phases of development for the PI3-K\/mTOR pathway.","journal-title":"Clin Cancer Res"},{"key":"38_CR34","doi-asserted-by":"crossref","first-page":"5241","DOI":"10.1016\/S0021-9258(17)37680-9","volume":"269","author":"CJ Vlahos","year":"1994","unstructured":"Vlahos CJ, Matter WF, Hui KY, Brown RF: A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 1994, 269:5241\u20135248.","journal-title":"J Biol Chem"},{"key":"38_CR35","doi-asserted-by":"publisher","first-page":"3102","DOI":"10.1158\/1078-0432.CCR-04-1857","volume":"11","author":"S Uddin","year":"2005","unstructured":"Uddin S, Hussain AR, Al-Hussein KA, et al.: Inhibition of phosphatidylinositol 3'-kinase\/AKT signaling promotes apoptosis of primary effusion lymphoma cells. Clin Cancer Res 2005, 11:3102\u20133108.","journal-title":"Clin Cancer Res"},{"key":"38_CR36","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1158\/1535-7163.MCT-05-0068","volume":"4","author":"Y Shi","year":"2005","unstructured":"Shi Y, Yan H, Frost P, et al.: Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor\/insulin receptor substrate-1\/phosphatidylinositol 3-kinase cascade. Mol Cancer Ther 2005, 4:1533\u20131540.","journal-title":"Mol Cancer Ther"},{"key":"38_CR37","doi-asserted-by":"publisher","first-page":"4053","DOI":"10.1182\/blood-2005-08-3434","volume":"107","author":"T Hideshima","year":"2006","unstructured":"Hideshima T, Catley L, Yasui H, et al.: Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 2006, 107:4053\u20134062.","journal-title":"Blood"},{"key":"38_CR38","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1016\/S0959-8049(02)00127-2","volume":"38","author":"M Crul","year":"2002","unstructured":"Crul M, Rosing H, de Klerk GJ, et al.: Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours. Eur J Cancer 2002, 38:1615\u20131621.","journal-title":"Eur J Cancer"},{"key":"38_CR39","doi-asserted-by":"publisher","first-page":"7450","DOI":"10.1158\/1078-0432.CCR-03-0406","volume":"10","author":"L Van Ummersen","year":"2004","unstructured":"Van Ummersen L, Binger K, Volkman J, et al.: A phase I trial of perifosine (NSC 639966) on a loading dose\/maintenance dose schedule in patients with advanced cancer. Clin Cancer Res 2004, 10:7450\u20137456.","journal-title":"Clin Cancer Res"},{"key":"38_CR40","doi-asserted-by":"crossref","first-page":"727","DOI":"10.7164\/antibiotics.28.727","volume":"28","author":"SN Sehgal","year":"1975","unstructured":"Sehgal SN, Baker H, Vezina C: Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J Antibiot (Tokyo) 1975, 28:727\u2013732.","journal-title":"J Antibiot (Tokyo)"},{"key":"38_CR41","doi-asserted-by":"crossref","first-page":"721","DOI":"10.7164\/antibiotics.28.721","volume":"28","author":"C Vezina","year":"1975","unstructured":"Vezina C, Kudelski A, Sehgal SN: Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot (Tokyo) 1975, 28:721\u2013726.","journal-title":"J Antibiot (Tokyo)"},{"key":"38_CR42","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/S0009-9120(98)00045-9","volume":"31","author":"SN Sehgal","year":"1998","unstructured":"Sehgal SN: Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem 1998, 31:335\u2013340.","journal-title":"Clin Biochem"},{"key":"38_CR43","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1093\/annonc\/mdi113","volume":"16","author":"S Vignot","year":"2005","unstructured":"Vignot S, Faivre S, Aguirre D, Raymond E: mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 2005, 16:525\u2013537.","journal-title":"Ann Oncol"},{"key":"38_CR44","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1182\/blood-2004-06-2494","volume":"105","author":"C Recher","year":"2005","unstructured":"Recher C, Beyne-Rauzy O, Demur C, et al.: Antileukemic activity of rapamycin in acute myeloid leukemia. Blood 2005, 105:2527\u20132534.","journal-title":"Blood"},{"key":"38_CR45","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1182\/blood-2005-05-1935","volume":"107","author":"DT Teachey","year":"2006","unstructured":"Teachey DT, Obzut DA, Cooperman J, et al.: The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL. Blood 2006, 107:1149\u20131155.","journal-title":"Blood"},{"key":"38_CR46","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1182\/blood.V106.11.2980.2980","volume":"106","author":"DR Rizzieri","year":"2005","unstructured":"Rizzieri DR, Feldman E, Moore JO: A phase 2 clinical trial of AP23573, an mTOR inhibitor, in patients with relapsed or refractory hematologic malignancies [abstract]. Blood 2005, 106:2980.","journal-title":"Blood"},{"key":"38_CR47","doi-asserted-by":"publisher","first-page":"5347","DOI":"10.1200\/JCO.2005.13.466","volume":"23","author":"TE Witzig","year":"2005","unstructured":"Witzig TE, Geyer SM, Ghobrial I, et al.: Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 2005, 23:5347\u20135356. The first trial to demonstrate clinical activity of the mTOR inhibitors in lymphoma.","journal-title":"J Clin Oncol"},{"key":"38_CR48","first-page":"1433","volume":"90","author":"S Hipp","year":"2005","unstructured":"Hipp S, Ringshausen I, Oelsner M, et al.: Inhibition of the mammalian target of rapamycin and the induction of cell cycle arrest in mantle cell lymphoma cells. Haematologica 2005, 90:1433\u20131434.","journal-title":"Haematologica"},{"key":"38_CR49","doi-asserted-by":"crossref","first-page":"561s","DOI":"10.1200\/jco.2005.23.16_suppl.561","volume":"23","author":"TE Witzig","year":"2005","unstructured":"Witzig TE, Ansell SM, Geyer SM, et al.: Anti-tumor activity of low-dose single agent CCI-779 for relapsed mantle cell lymphoma: a phase II trial in the North Central Cancer Treatment Group [abstract 6503]. Proc Am Soc Clin Oncol 2005, 23:561s.","journal-title":"Proc Am Soc Clin Oncol"},{"key":"38_CR50","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1097\/01.TP.0000063934.89714.19","volume":"75","author":"M Majewski","year":"2003","unstructured":"Majewski M, Korecka M, Joergensen J, et al.: Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograftprotecting doses. Transplantation 2003, 75:1710\u20131717.","journal-title":"Transplantation"},{"key":"38_CR51","doi-asserted-by":"publisher","first-page":"4285","DOI":"10.1073\/pnas.080068597","volume":"97","author":"M Majewski","year":"2000","unstructured":"Majewski M, Korecka M, Kossev P, et al.: The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: a potential approach to prevention and treatment of posttransplant lymphoproliferative disorders. Proc Natl Acad Sci U S A 2000, 97:4285\u20134290.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"38_CR52","doi-asserted-by":"publisher","first-page":"4188","DOI":"10.1182\/blood-2004-06-2281","volume":"104","author":"N Raje","year":"2004","unstructured":"Raje N, Kumar S, Hideshima T, et al.: Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. Blood 2004, 104:4188\u20134193.","journal-title":"Blood"},{"key":"38_CR53","doi-asserted-by":"publisher","first-page":"4181","DOI":"10.1182\/blood-2004-03-1153","volume":"104","author":"P Frost","year":"2004","unstructured":"Frost P, Moatamed F, Hoang B, et al.: In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model. Blood 2004, 104:4181\u20134187.","journal-title":"Blood"},{"key":"38_CR54","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/1479-5876-3-39","volume":"3","author":"KR Molhoek","year":"2005","unstructured":"Molhoek KR, Brautigan DL, Slingluff CL Jr: Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor rapamycin. J Transl Med 2005, 3:39.","journal-title":"J Transl Med"},{"key":"38_CR55","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.cell.2004.12.040","volume":"120","author":"I Beuvink","year":"2005","unstructured":"Beuvink I, Boulay A, Fumagalli S, et al.: The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 2005, 120:747\u2013759.","journal-title":"Cell"},{"key":"38_CR56","doi-asserted-by":"publisher","first-page":"4261","DOI":"10.1182\/blood-2004-11-4468","volume":"106","author":"Q Xu","year":"2005","unstructured":"Xu Q, Thompson JE, Carroll M: mTOR regulates cell survival after etoposide treatment in primary AML cells. Blood 2005, 106:4261\u20134268.","journal-title":"Blood"},{"key":"38_CR57","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/nature02369","volume":"428","author":"HG Wendel","year":"2004","unstructured":"Wendel HG, De Stanchina E, Fridman JS, et al.: Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 2004, 428:332\u2013337.","journal-title":"Nature"},{"key":"38_CR58","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1182\/blood-2004-01-0240","volume":"105","author":"PG Smith","year":"2005","unstructured":"Smith PG, Wang F, Wilkinson KN, et al.: The phosphodiesterase PDE4B limits cAMP-associated PI3K\/AKTdependent apoptosis in diffuse large B-cell lymphoma. Blood 2005, 105:308\u2013316.","journal-title":"Blood"},{"key":"38_CR59","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1182\/blood-2004-06-2078","volume":"105","author":"L Lal","year":"2005","unstructured":"Lal L, Li Y, Smith J, et al.: Activation of the p70 S6 kinase by all-trans-retinoic acid in acute promyelocytic leukemia cells. Blood 2005, 105:1669\u20131677.","journal-title":"Blood"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-006-0038-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-006-0038-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-006-0038-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-006-0038-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T10:34:15Z","timestamp":1659090855000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-006-0038-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,8]]},"references-count":59,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,8]]}},"alternative-id":["38"],"URL":"https:\/\/doi.org\/10.1007\/s11864-006-0038-1","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,8]]},"assertion":[{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}